FDA delays Thrombin review

08/23/2007 | SeattlePI.com

The FDA has postponed completing a review of ZymoGenetics' blood-clotting drug Thrombin so it can further examine manufacturing data, the company announced. The review now is expected to be completed by Jan. 17 of next year.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Director of Operations - GBS
Mayo Clinic
Rochester, MN